I am testing compounds on the patient's primary cancer cells as well as a cell line. Generally, I see better activity in cell lines compared to primary cells. Surprisingly I am seeing the wonderful activity of few compounds in patient-derived primary cells but not in the cell lines. Could anybody please explain the possible reason for better activity in PDCs than cell lines?